Management of Prolonged Menstrual Bleeding in Reproductive‑Age Women

Immediate Assessment

In women presenting with prolonged menstrual bleeding, hemodynamic instability is defined as blood saturating a large pad or tampon each hour for ≥ 4 hours; such patients require urgent evaluation. (American Heart Association guideline; high‑quality evidence) 1

A 7‑day high‑dose oral progestin course (medroxyprogesterone acetate 20 mg TID or norethindrone acetate 5 mg TID) stops acute bleeding in most patients within 24–48 hours and is the most effective short‑term intervention. (American Heart Association guideline; older but consistent practice) 1

After acute control, a cyclic regimen of medroxyprogesterone acetate 10 mg daily on days 16‑25 of each cycle reduces menstrual blood loss by ≈ 87 % but is less effective than a levonorgestrel‑releasing intrauterine system (LNG‑IUS). (American Heart Association guideline; moderate evidence) 1
This regimen initially produces irregular bleeding, which typically stabilizes to light bleeding over subsequent cycles. (American Heart Association guideline; moderate evidence) 1

Insertion of an LNG‑IUS after bleeding is controlled achieves a 71‑95 % reduction in menstrual blood loss, representing the most effective long‑term option. (American Heart Association guideline; high‑quality evidence) 1
The LNG‑IUS acts primarily at the endometrial level with minimal systemic hormone absorption. (American Heart Association guideline; high‑quality evidence) 1

Hormonal therapy (including high‑dose progestins) should be avoided or used with extreme caution in patients with spontaneous coronary artery dissection or established cardiovascular disease, as these conditions constitute relative contraindications. (American Heart Association guideline; moderate evidence) 1
Non‑steroidal anti‑inflammatory drugs (e.g., mefenamic acid or naproxen) taken for 5‑7 days during active bleeding can lower blood loss by 20‑50 %, but they are contraindicated in women with cardiovascular disease because of increased risk of myocardial infarction and thrombosis. (American Heart Association guideline; moderate evidence) 1

Persistent hemodynamic instability despite a high‑dose progestin course warrants escalation to specialist care. (American Heart Association guideline; moderate evidence) 1
When medical therapy fails (e.g., after 6 weeks) and fertility preservation is not a goal, endometrial ablation or hysterectomy should be considered. (American Heart Association guideline; moderate evidence) 1

The superiority of LNG‑IUS over oral progestins is supported by recent high‑quality guidelines demonstrating a 71‑95 % reduction in menstrual blood loss. (American Heart Association guideline; high‑quality evidence) 1
Cyclic oral progestins, while less effective than LNG‑IUS, remain a reasonable alternative when intrauterine device placement is not feasible. (American Heart Association guideline; moderate evidence) 1

The levonorgestrel-releasing intrauterine device (LNG-IUS) is the single most effective progesterone-based treatment for heavy menstrual bleeding, achieving 71-95% reduction in menstrual blood loss, according to the American College of Cardiology 2, 3
The LNG-IUS works primarily at the endometrial level with minimal systemic progesterone absorption, as recommended by the American College of Cardiology 2
Cyclic oral progestin reduces bleeding by 87% and typically results in irregular bleeding with eventual reduction to light bleeding only, as stated by the American College of Cardiology 2, 3
The LNG-IUS is more effective than oral medications, with 22% of users experiencing complete amenorrhea, as reported by the Centers for Disease Control and Prevention 4, 5

High-dose oral or injectable progestin-only medications may be considered short-term in hemodynamically unstable women when bleeding is not controlled, as recommended by the American College of Cardiology 2, 3
First-line treatment for chronic heavy menstrual bleeding is the LNG-IUS, which provides a 71-95% reduction in menstrual blood loss, according to the American College of Cardiology 2, 6
Second-line treatment for chronic heavy menstrual bleeding is cyclic oral progestins, which reduce bleeding by 87%, as stated by the American College of Cardiology 2, 6

In women with spontaneous coronary artery dissection, hormonal therapy including progesterone is relatively contraindicated and requires careful clinical judgment, as recommended by the American College of Cardiology 2, 3
Hormone replacement therapy should not be used for secondary prevention in women with established coronary artery disease, according to the American College of Cardiology 7

Enhanced counseling about expected bleeding patterns reduces discontinuation rates, as reported by the Centers for Disease Control and Prevention 4, 5, 6
Patients should be reassured that irregular bleeding patterns are generally not harmful, as stated by the Centers for Disease Control and Prevention 4, 5, 6

The Centers for Disease Control and Prevention recommends that for unscheduled spotting or light bleeding with LNG-IUS, NSAIDs can be used for 5-7 days of treatment 8
The Centers for Disease Control and Prevention suggests that for heavy or prolonged bleeding with LNG-IUS, NSAIDs (5-7 days) or hormonal treatment with combined oral contraceptives or estrogen (10-20 days) can be used if medically eligible 8
According to the MMWR Recommendations and Reports, if bleeding persists or the woman finds it unacceptable despite progesterone treatment, counseling on alternative methods and offering another method is recommended 8